THYMIC STROMAL LYMPHOPOIETIN (TSLP) IS A TUMOR MICROENVIRONMENT MODULATOR: RELEVANCE IN THE PATHOGENESIS OF GLIOBLASTOMA AS TUMOR IMMUNOMODULATOR

CORONEL JUAN VALENTÍN, ; INFANTE ALEJANDRA, ; JANCIC CAROLINA C, ; ROSSO DAVID A, ; ROSATO MICAELA, ; ITURRIZAGA JUAN, ; RABADÁN ALEJANDRA,; REMES LENICOV FEDERICO, ; SALAMONE GABRIELA

Congreso; LXIX Reunión Anual de la Sociedad Argentina de Inmunología; 2021

Background: Glioblastoma (GBM) is the most devastating brain tumor, with an associated poor prognosis. Despite the advances in surgery and chemoradiation, the survival of GBM patients has not improved significantly in the past three decades. Thymic stromal lymphopoietin (TSLP) is a cytokine produced primarily by activated epithelial cells. TSLP has been shown to be a key factor in maintaining immune homeostasis and regulating inflammatory responses at mucosal barriers, recent studies have found an expanding role for TSLP in inflammatory diseases and cancer. This work aimed to elucidate the relevance of TSLP in the interaction between neutrophils and GBM cells. First, we evaluated the production of TSLP by tumor cells through RT-PCR and then, we determined whether the TSLP treatment affects the cross-talk between neutrophils and tumor GBM cells. For those purposes human U251 cell line or tumoral cells obtained from a GBM patient (GBM-b) were co-cultured with human neutrophils. We observed that the U251 cell line or the primary cell culture incubated with Epidermal Growth Factor (EGF) produced TSLP (p